secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001564590-21-056810
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q3 lung diagnostic revenue up 51% YoY; launches 72-hour NGS test
-------------------------------------------------------------------------

- Total revenue $6.5M; lung diagnostic revenue $4.5M (+51% YoY), services $1.5M (+133%), COVID-19 testing $0.5M (-91%).
- Gross margin 58% (up from 40% in Q2 2021); operating expenses $16.9M (+46%).
- Net loss $11.5M (+30%); includes $3.1M non-cash PPP loan forgiveness gain.
- Cash and cash equivalents $47.9M as of Sept 30, 2021.
- Launched 72-hour liquid NGS test ahead of schedule; broad US launch targeted for Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000156459021056810/0001564590-21-056810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000156459021056810/bdsx-8k_20211115.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer